Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Latest updates in trials investigating treatments of neurological malignancies

Guiseppe Lombardi • 23 Oct 2023
ESMO 2023
Brain Tumor Glioblastoma Glioma Pemigatinib Temozolomide Trotabresib Vorasidenib
INDIGO

Giuseppe Lombardi, MD, PhD, Veneto Institute of Oncology, Padua, Italy, discusses the latest findings and results in neuro-oncology, including updates from the Phase III INDIGO (NCT04164901) trial, a Phase I study (NCT04324840) into the combination of trotabresib and temozolomide, as well as prognosis biomarkers in gliomas and pemigatinib for the treatment of patients with meningioma. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Guiseppe Lombardi

3:30
Future directions in the treatment of glioblastoma
Guiseppe Lombardi • 23 Oct 2023
1:53
Utilizing regorafenib in the treatment of patients with recurrent glioblastoma
Guiseppe Lombardi • 23 Oct 2023
3:47
REGOMA-OS: a real-world study into the use of regorafenib for patients with recurrent glioblastoma
Guiseppe Lombardi • 23 Oct 2023

Related Videos

2:19
Clinical advances in brain cancer: AZD1390 and CAR-T cells in glioma
Patrick Wen • 12 Apr 2024
1:52
ACTION: ONC201 in H3 K27M–mutant diffuse midline glioma
Patrick Wen • 12 Apr 2024
1:07
Genomic predictors of adverse events in glioblastoma
Patrick Wen • 12 Apr 2024
2:48
Clinical advances in the management of gliomas
Patrick Wen • 12 Apr 2024
The content of VJOncology is intended for healthcare professionals